Ministry of Health registered first romiplostim biosimilar


Generium, a Russian company, has just obtained a marketing authorization for the “Stimplate” drug. Treatment for primary immune thrombocytopenia in adults and children over one year who haven’t responded to other treatments. This is the first Russian biosimilar of an orphan drug with the International nonproprietary name “romiplostim” (Enplate, Amgen).

“The synthesized protein romiplostim stimulates the formation of platelets, thereby normalizing the blood clotting function,” Generium explained. Romiplostim has been included in Russia’s list of vital and essential drugs, ensuring that patients will receive funding for their treatment from regional budgets.